Document:

Exhibit 10.8

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “Agreement”),
effective as of [______], 2013 is entered into by and between Silver Eagle Acquisition Corp. (the “Company”)
and James A. Graf (the “Consultant”).

 

WHEREAS, the Consultant has experience providing
financial advisory services and the Company wishes to retain the Consultant to provide financial advisory services to the Company
on the terms and conditions set forth in this Agreement;

 

NOW, THEREFORE, in consideration of the
mutual promises herein made, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged
and agreed, IT IS HEREBY AGREED AS FOLLOWS:

 

1.            Engagement. The Company hereby
engages the Consultant, and the Consultant hereby agrees to serve the Company to the best of his ability to provide financial advisory
services to the Company during the Term (as defined below) as and when requested by the Company (the “Consulting Obligations”).
The Consultant shall devote his attention, skill, energy and efforts to faithfully and effectively perform his duties hereunder.

 

2.            Term. The Consultant’s
obligation to perform the Consulting Obligations and the Company’s obligations to compensate the Consultant hereunder shall
terminate on the earlier of (i) the date which is 30 days from the date one party sends written notice to the other party with
respect to the termination of this Agreement, which a party can exercise at any time and (ii) the closing date of the Company’s
initial business combination as such term is used in the Company’s Registration Statement (No. 333-189498) on Form S-1, as
amended, (the “Term”) and upon which date this Agreement other than the provisions of Sections 5 through 11
applicable thereto shall terminate.

 

3.            Fees.
During the Term, in consideration for the Consultant’s services to be performed hereunder, the Company shall pay the
Consultant a consulting fee, monthly in arrears, at the rate of $15,000 per month for each month (or portion thereof) that the Company engages
the Consultant to perform consulting services plus, in the event that the Consultant is no longer receiving medical insurance from
an employer, an additional amount per month to reimburse the Consultant for the purchase of such insurance.

 

4.            Expenses. During the Term,
the Company shall reimburse the Consultant for the Consultant’s reasonable and documented travel expenses incurred at the
request of the Company. The Consultant shall not be entitled to any other benefits from the Company or its affiliates.

 

5.            Covenants of the Consultant.

 

(A)            Confidential Information. “Confidential
Information” means all information (whether written or oral) and materials concerning the Company or any business or
assets that the Company may target for acquisition which the Company and/or its affiliates or their employees or representatives
has furnished or may hereafter furnish to the Consultant or which the Consultant learns in connection with the performance of his
duties hereunder. Confidential Information specifically includes, but is not limited to, pricing, costs, other financial information,
drawings, artwork, designs, formulations, processes, patent applications, research procedures, models, prototypes, samples, specifications,
test results, analyses, software, forecasts and studies. Notwithstanding the foregoing, Confidential Information does not include
any information or materials which the Consultant can clearly demonstrate (a) is or becomes generally available to the public other
than as a result of an unauthorized disclosure by the Consultant, (b) is or becomes available to the Consultant from a third party,
other than on a confidential basis from the Company or its affiliates, which third party represents to the Consultant that it is
entitled to disclose such information, (c) was known to the Consultant prior to receipt thereof by the Consultant from the Company
or its affiliates, or (d) is approved for release by the express prior written authorization of Company or its affiliates and then
only after such approval and only for the purpose specified.

 

    	 

    	 

    

 

(B)            Confidentiality and Non-Use.
The Consultant shall keep or cause to be kept in strict confidence all Confidential Information and shall not use it or disclose
it to anyone except in connection with the fulfillment of the Consulting Obligations (and, in the case of disclosure to a third
party, only if the third party to whom it is disclosed agrees to keep it confidential in accordance with this Agreement). If the
Consultant makes any copies of the Confidential Information or any abstracts or summaries thereof or references thereto in any
other document, he will keep a record in each such instance. Upon the Company’s written request, the Consultant will either
destroy or return to the Company all Confidential Information which is in tangible form, including any copies thereof which the
Consultant may have made, and the Consultant will destroy all abstracts and summaries thereof and destroy or delete all references
thereto in his documents, and certify to the Company that he has done so. If the Company notifies the Consultant in writing as
to any of the Confidential Information which it does not wish copied, the Consultant shall so comply and upon the Company’s
written request shall certify such compliance to the Company in writing.

 

(C)            Legal Requirement to Disclose.
In the event that the Consultant or to the Consultant’s knowledge anyone to whom the Consultant transmits the Confidential
Information pursuant to this Agreement becomes legally compelled to disclose any of the Confidential Information, the Consultant
will provide the Company with prompt notice, if lawful, so that the Company may seek a protective order or other appropriate remedy
or waive compliance with the provisions of this Agreement. If such protective order or other remedy is not obtained, or if the
Company waives compliance with the provisions of this Agreement, the Consultant will furnish only that portion of the Confidential
Information which the Consultant is advised by its counsel is legally required to be furnished.

 

(D)            Conduct. The Consultant agrees
that he will not, directly or indirectly, individually or in concert with others, engage in any conduct or make any statement calculated
or likely to have the effect of undermining, disparaging or otherwise reflecting poorly upon the Company or its affiliates or their
good will, products or business opportunities, or in any manner detrimental to the Company, its successors and assigns, and its
affiliates, their shareholders, officers, directors, or employees, past, present and future. The foregoing shall apply (but not
be limited to) oral, written or other communications with former, existing and potential employees, officers, directors, customers
and suppliers.

 

    	 

    	 

    

 

(E)            Remedies/Specific Performance.
In the event of a breach or a threatened breach of any of the provisions of this Section 5, the Company and its affiliates, in
addition and supplementary to other rights and remedies existing in its favor, may apply to any court of law or equity of competent
jurisdiction for specific performance and/or injunctive or other relief in order to enforce or prevent any violations of the provisions
hereof (without posting a bond or other security).

 

6.            Benefits, etc. The Consultant
shall be responsible for all personal income and other payroll taxes payable with respect to compensation received hereunder and
accepts exclusive liability for all contributions required under social security laws and unemployment compensation laws or other
payments under any laws of similar character for the Consultant. The Consultant shall not be entitled to receive any benefits under
any employee benefit plan or program of any kind maintained by the Company.

 

7.            Entire Agreement. This Agreement
constitutes the entire agreement between the Consultant and the Company with respect to its subject matter and supersedes all prior
discussions and agreements relating to its subject matter.

 

8.            Enforceability. Any term or
provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity
or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision
in any other situation or in any other jurisdiction. If any provision of this Agreement shall, in whole or in part, become or be
held invalid or unenforceable, all other provisions of this Agreement shall remain in full force and effect. The parties undertake
to replace such invalid or unenforceable provisions with such valid and enforceable provisions, which accomplish as far as possible
the purpose and intent of the parties with respect to the invalid or unenforceable provision. The same shall apply accordingly
to any situation not contemplated under or covered by this Agreement.

 

9.            Counterparts; Assignment; Notices.
This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall
constitute one and the same instrument. The rights and obligations of this Agreement shall bind and inure to the benefit of the
parties and their respective successors and assigns. Except as expressly provided herein or therein, the rights and obligations
of this Agreement may not be assigned by the Consultant without the prior written consent of Company. All notices, requests, demands,
claims, and other communications hereunder shall be in writing.

 

10.            Amendments and Waivers. This
Agreement may not be modified, amended, supplemented, canceled or discharged, except by written instrument executed by the Company
and the Consultant. No failure to exercise, and no delay in exercising, any right, power or privilege under this Agreement shall
operate as a waiver, nor shall any single or partial exercise of any right, power or privilege hereunder preclude the exercise
of any other right, power or privilege. No waiver of any breach of any provision shall be deemed to be a waiver of any preceding
or succeeding breach of the same or any other provision, nor shall any waiver be implied from any course of dealing between the
parties.

 

    	 

    	 

    

 

11.            Governing Law and Arbitration.
All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by, and construed in accordance with, the laws of the State of California, without giving effect to any choice of law or conflict
of law rules or provisions (whether of the State of California or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of California. The parties agree that all disputes, legal actions, suits and proceedings
arising out of or relating to this Agreement shall, in lieu of a jury or other civil trial, be settled by final and binding arbitration
before a single arbitrator in Los Angeles, California and shall be conducted in accordance with then-current rules of the American
Arbitration Association. This agreement to arbitrate includes all claims whether arising in tort or contract and whether arising
under statute or common law. The obligation to arbitrate such claims shall continue forever, and the arbitrator shall have jurisdiction
to determine the arbitrability of any claim. The arbitrator shall have the power to award any remedies, including attorneys’
fees and costs, available under applicable law. The arbitrator shall not have the authority to add to, subtract from or modify
any of the terms of this Agreement. Judgment on any award rendered by the arbitrator may be entered and enforced by any court having
jurisdiction thereof. The costs of the arbitration, including the arbitrator’s fees, shall be borne equally by the parties
to the arbitration, unless the arbitrator orders otherwise, and each party shall be responsible for paying its own other costs
for the arbitration, including, but not limited to, attorneys’ fees, witness fees, transcript fees, or other litigation expenses
that such party would otherwise be required to bear in a court action, unless the arbitrator orders otherwise. Notwithstanding
the foregoing, the Company shall be entitled to apply to any court of law or equity of competent jurisdiction for the relief specified
in Section 5(E) hereof.

 

[SIGNATURE PAGE FOLLOWS]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Consultant and the Company have executed
this Agreement effective as of the date first written above.

 

	 	 	Silver Eagle Acquisition Corp.
	 	 	 
	 	 	By:	 
	James A. Graf	 	 	Name: Jeff Sagansky
	 	 	 	Title: PresidentTHIS OPTION HAS NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR SECURITIES LAWS OF ANY STATE, AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED UNLESS
REGISTERED PURSUANT TO APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS OR EXEMPT FROM THE REGISTRATION REQUIREMENTS
THEREOF.

 

AMENDED AND RESTATED

GENEREX BIOTECHNOLOGY CORPORATION

2006 STOCK PLAN

NONQUALIFIED STOCK OPTION GRANT

 

This STOCK OPTION GRANT,
dated as of April 1, 2013 (the “Date of Grant”), is delivered by Generex Biotechnology Corporation (the “Company”)
to Mark Fletcher, an employee of the Company (the “Grantee”).

 

RECITALS

 

A.           The
Amended and Restated Generex Biotechnology Corporation 2006 Stock Plan (the “Plan”) provides for the grant of
options to purchase shares of common stock of the Company. The Board of Directors of the Company (the “Board”)
has decided to make a stock option grant. A copy of the Plan is attached as Exhibit A to this Agreement. Capitalized terms
used in this Agreement and not otherwise defined shall have the meanings assigned such terms in the Plan.

 

B.           The
Board is authorized to appoint a committee or individual to administer the Plan. If a committee or individual is appointed, all
references in this Agreement to the “Board” shall be deemed to refer to the committee or individual.

 

NOW, THEREFORE, the
parties to this Agreement, intending to be legally bound hereby, agree as follows:

 

1.           Grant
of Option.

 

(a)          Subject
to the terms and conditions set forth in this Agreement and in the Plan, the Company hereby grants to the Grantee an incentive
stock option (the “Option”) to purchase up to five million, one hundred forty-three thousand, seven hundred
and eighty-seven (5,143,787) shares of common stock of the Company (“Shares”) at an exercise price of $0.001
per Share. The Option shall become exercisable according to Paragraph 2 below.

 

(b)          Under
the terms and conditions contained in the Plan, the Option is granted as a nonqualified stock option and is not an incentive stock
options under section 422 of the Internal Revenue Code of 1986, as amended.

 

2.           Exercisability
of Option. The Option shall be exercisable as set forth in the following schedule provided that the Grantee is employed
by or providing service to the Company (as defined in the Plan) on the applicable date of exercise: 5,143,787 shares will
be immediately exercisable as of the Date of Grant.

 

    	 

    	 

    

 

3.           Term
of Option.

 

(a)          The
Option shall have a term of five (5) years from the Date of Grant and shall terminate at the expiration of that period, unless
it is terminated at an earlier date pursuant to the provisions of this Agreement or the Plan.

 

(b)          Unless
otherwise specified by the Board, the Option shall automatically terminate on the date on which the Grantee ceases to be employed
or provide service to the Company for any reason, except for the happening of any of the events described in Paragraph 3(c).

 

(c)          The
Option shall automatically upon the happening of the first of the following events:

 

(i)          The
date on which the Board determines that the Grantee has engaged in conduct that constitutes Cause at any time while the Grantee
is employed by or providing service to the Company. In addition, notwithstanding the other provisions of this Paragraph 3, if the
Board determines that the Grantee has engaged in conduct that constitutes Cause after the Grantee’s termination of employment
or service for any reason, the Option shall immediately terminate.

 

(ii)         The
expiration of the 90-day period after the Grantee ceases to provide services to the Company, as a result of a termination of service
without Cause or if the Grantee voluntarily terminated employment or service and provided the Company with at least 90 days advance
written notice of the effective date of such termination of employment or service with the Company.

 

(iii)        The
expiration of the one-year period after the Grantee ceases to provide services to the Company on account of the Grantee’s
Disability.

 

(iv)        The
expiration of the one-year period after the Grantee ceases to be employed by or provide services to the Company, if the Grantee
dies while employed by or in the service of the Company.

 

Notwithstanding the foregoing, in no event
may the Option be exercised after the date that is five (5) years from the Date of Grant. Any portion of the Option that is not
exercisable at the time the Grantee ceases to be employed by or provide service to the Company shall immediately terminate.

 

4.           Exercise
Procedures.

 

(a)          Subject
to the provisions of the foregoing Paragraphs, the Grantee may exercise part or all of the exercisable Option by giving the Board
written notice of intent to exercise in the manner provided in this Agreement and Section 5(h) of the Plan, specifying the number
of whole Shares as to which the Option is to be exercised. On the delivery date, the Grantee shall pay the exercise price (i) in
cash, (ii) with the approval of the Board, by delivering Shares of the Company which shall be valued at their fair market value
on the date of delivery, (iii) payment through a broker in accordance with procedures permitted by Regulation T of the Federal
Reserve Board, which procedures may or may not be available, or (iv) by such other method as the Board may approve. The Board may
impose from time to time such limitations as it deems appropriate on the use of Shares of the Company to exercise the Option.

 

    	 

    	 

    

 

(b)          All
obligations of the Company under this Agreement shall be subject to the rights of the Company as set forth in the Plan to withhold
amounts required to be withheld for any taxes, if applicable. Subject to Board approval, the Grantee may elect to satisfy any income
tax withholding obligation of the Company with respect to the Option by having Shares withheld up to an amount that does not exceed
the minimum applicable withholding tax rate for federal (including FICA), state and local tax liabilities.

 

(c)          The
obligation of the Company to deliver Shares upon exercise of the Option shall be subject to all applicable laws, rules, and regulations
and such approvals by governmental agencies as may be deemed appropriate by the Board, including such actions as Company counsel
shall deem necessary or appropriate to comply with relevant securities laws and regulations.

 

5.           [Intentionally
Omitted.]

 

6.           Change
of Control.  The provisions of the Plan applicable to a Change of Control shall apply to the Option, and, in
the event of a Change of Control, the Board may take such actions as it deems appropriate pursuant to the Plan.

 

7.           Cancellation
and Rescission of Options.  The Grantee acknowledges and understands that the Option is subject to the cancellation
and rescission provisions of Section 12 of the Plan.

 

8.           Restrictions
on Exercise.  Only the Grantee may exercise the Option during the Grantee’s lifetime. After the Grantee’s
death, the Option shall be exercisable (subject to the limitations specified in the Plan) solely by the legal representatives of
the Grantee, or by the person who acquires the right to exercise the Option by will or by the laws of descent and distribution,
to the extent that the Option is exercisable pursuant to this Agreement.

 

9.           Grant
Subject to Plan Provisions.  This grant is made pursuant to the Plan, the terms of which are incorporated herein
by reference, and in all respects shall be interpreted in accordance with the Plan. The grant and exercise of the Option are subject
to the provisions of the Plan and to interpretations, regulations and determinations concerning the Plan established from time
to time by the Board in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (i)
rights and obligations with respect to withholding taxes, (ii) the registration, qualification or listing of the Shares, (iii)
changes in capitalization of the Company and (iv) other requirements of applicable law. The Board shall have the authority to interpret
and construe the Option pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder.

 

    	 

    	 

    

 

10.          No
Employment or Other Rights.  The grant of the Option shall not confer upon the Grantee any right to be retained
by or in the employ or service of the Company and shall not interfere in any way with the right of the Company to terminate the
Grantee’s employment or service at any time. The right of the Company to terminate at will the Grantee’s employment
or service at any time for any reason is specifically reserved.

 

11.          No
Stockholder Rights.  Neither the Grantee, nor any person entitled to exercise the Grantee’s rights in the
event of the Grantee’s death, shall have any of the rights and privileges of a stockholder with respect to the Shares subject
to the Option, until certificates for Shares have been issued upon the exercise of the Option.

 

12.          Assignment
and Transfers.  The rights and interests of the Grantee under this Agreement may not be sold, assigned, encumbered
or otherwise transferred except, in the event of the death of the Grantee, by will or by the laws of descent and distribution.
In the event of any attempt by the Grantee to alienate, assign, pledge, hypothecate, or otherwise dispose of the Option or any
right hereunder, except as provided for in this Agreement, or in the event of the levy or any attachment, execution or similar
process upon the rights or interests hereby conferred, the Company may terminate the Option by notice to the Grantee, and the Option
and all rights hereunder shall thereupon become null and void. The rights and protections of the Company hereunder shall extend
to any successors or assigns of the Company and to the Company’s parents, subsidiaries, and affiliates. This Agreement may
be assigned by the Company without the Grantee’s consent.

 

13.          Notice.  Any
notice to the Company provided for in this instrument shall be addressed to the Company in care of the President, 33 Harbor Square,
Suite 202, Toronto, Ontario, Canada, M5J 2G2, and any notice to the Grantee shall be addressed to such Grantee at the current address
shown on the books of the Company, or to such other address as the Grantee may designate to the Company in writing. Any notice
shall be delivered by hand, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and
deposited, postage prepaid, in a post office regularly maintained by the United States Postal Service or Canada Post.

 

[Signatures Appear on Following Page]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused its duly authorized officers to execute and attest this Agreement, and the Grantee has executed this Agreement,
effective as of the Date of Grant.

 

	 	GENEREX BIOTECHNOLOGY CORPORATION
	 	 	 
	 	Per:	/s/ Stephen Fellows
	 	Name:	Stephen Fellows
	 	Title:	Chief Financial Officer
	 	 	 
	 	Per:	/s/ Mark A. Fletcher 
	 	Name:	Mark A. Fletcher
	 	Title:	Chief Executive Officer and General Counsel
	 	 	 
	 	ACCEPTED:	 
	 	 	 
	 	/s/ Mark Fletcher
	 	Mark Fletcher, Grantee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]